Go Pro
NASDAQ:ADPT

Adaptive Biotechnologies Q2 2026 Earnings Report

Adaptive Biotechnologies logo
$21.06 0.00 (0.00%)
Closing price 07/10/2026 04:00 PM Eastern
Extended Trading
$20.83 -0.23 (-1.11%)
As of 05:09 AM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

Adaptive Biotechnologies EPS Results

Actual EPS
N/A
Consensus EPS
-$0.13
Beat/Miss
N/A
One Year Ago EPS
N/A

Adaptive Biotechnologies Revenue Results

Actual Revenue
N/A
Expected Revenue
$65.81 million
Beat/Miss
N/A
YoY Revenue Growth
N/A

Adaptive Biotechnologies Announcement Details

Quarter
Q2 2026
Time
After Market Closes
Conference Call Date
Wednesday, July 29, 2026
Conference Call Time
4:30PM ET

Conference Call Resources

Adaptive Biotechnologies Earnings Headlines

Trump Takes Emergency Action - Plus Elon Musk's New Venture
Elon Musk has quietly launched a new venture - one that has nothing to do with rockets, EVs, or Neuralink. Trump has issued emergency support to accelerate the rollout, and it's already live in multiple states. The Financial Times reports Sam Altman is personally calling people to build this for OpenAI. A few little-known companies control the entire supply chain - meaning anyone who wants access must go through them. Their stocks are available to buy right now.tc pixel
See More Adaptive Biotechnologies Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like Adaptive Biotechnologies? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Adaptive Biotechnologies and other key companies, straight to your email.

About Adaptive Biotechnologies

Adaptive Biotechnologies (NASDAQ:ADPT) is a clinical-stage biotechnology company that focuses on harnessing the adaptive immune system to transform the diagnosis and treatment of disease. Through proprietary immune receptor sequencing and analysis, the company decodes the genetic information of T-cell and B-cell receptors to identify signatures of immune response. Its core technology platform provides insights into immune-driven conditions, enabling more precise monitoring and targeted therapeutic development.

The company’s flagship product, immunoSEQ, offers high-throughput immune repertoire profiling for researchers and pharmaceutical partners. Adaptive also develops T-cell receptor (TCR) discovery services to support the discovery and development of novel TCR-based therapeutics. Its offerings span research services, clinical diagnostics, and collaborative programs with leading drug developers to advance immune-driven medicine.

Founded in 2009 and headquartered in Seattle, Washington, Adaptive Biotechnologies maintains research and operations facilities in North America and Europe. The company collaborates with global technology and life sciences organizations, including a strategic partnership with Microsoft to apply machine learning to immune data. Adaptive’s platform has been utilized in oncology, autoimmune and infectious disease research across multiple continents.

Adaptive Biotechnologies is led by co-founder and CEO Chad Robins, under whose guidance the firm continues to expand its molecular profiling capabilities and build a world-class immune medicine business.

View Adaptive Biotechnologies Profile